Screener
Olema Pharmaceuticals, Inc. OLMA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Olema Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:10 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-218156
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Depreciation and amortization expense | 119 | 128 |
| Non-cash lease expense | 301 | 287 |
| Non-cash interest income on marketable securities | (1,273) | (2,101) |
| Stock-based compensation expense, including employee stock purchase plan expense | 10,148 | 4,378 |
| Prepaid expenses and other current assets | 2,597 | 549 |
| Other assets and long-term deposits | (100) | (965) |
| Accounts payable | (5,681) | (4,309) |
| Other current liabilities | 1,304 | (11,248) |
Item 1. Financial Statements.
FAQ
- What is Olema Pharmaceuticals, Inc.'s stock-based comp?
- Olema Pharmaceuticals, Inc. (OLMA) reported stock-based comp of $10.15M in Q1 2026.
- How has Olema Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Olema Pharmaceuticals, Inc.'s stock-based comp increased by 131.8% year-over-year, from $4.38M to $10.15M.
- What is the long-term trend for Olema Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Olema Pharmaceuticals, Inc.'s stock-based comp has grown at a 2.5% compound annual growth rate (CAGR), from $15.91M to $17.59M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Olema Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude